Trial Profile
A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of CDX-3379 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2023
Price :
$35
*
At a glance
- Drugs CDX-3379 (Primary) ; Cetuximab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Celldex Therapeutics Inc
- 16 Dec 2021 Status changed from completed to discontinued.
- 27 Apr 2021 Status changed from active, no longer recruiting to completed.
- 03 Nov 2020 Planned End Date changed from 1 Oct 2020 to 1 Aug 2021.